Kala Pharmaceuticals Inc
NASDAQ:KALA
Kala Pharmaceuticals Inc
NASDAQ:KALA
Price:
0.38
USD
-5.94%
Market Closed
Market Cap:
$10.6m
Balance Sheet
Balance Sheet Decomposition
Kala Pharmaceuticals Inc
Kala Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Kala Pharmaceuticals Inc
Kala Pharmaceuticals Inc
Balance Sheet
Kala Pharmaceuticals Inc
Kala Pharmaceuticals Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
5
|
11
|
6
|
46
|
115
|
171
|
85
|
77
|
92
|
71
|
51
|
51
|
|
| Cash |
5
|
11
|
6
|
46
|
115
|
171
|
85
|
77
|
92
|
71
|
51
|
51
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
76
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
13
|
10
|
18
|
1
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
12
|
10
|
15
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
2
|
1
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
4
|
5
|
5
|
9
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
2
|
0
|
1
|
1
|
2
|
3
|
6
|
14
|
2
|
2
|
|
| Total Current Assets |
6
|
11
|
8
|
46
|
115
|
177
|
106
|
171
|
124
|
86
|
53
|
53
|
|
| PP&E Net |
1
|
1
|
1
|
1
|
1
|
32
|
33
|
31
|
4
|
0
|
3
|
2
|
|
| PP&E Gross |
1
|
1
|
1
|
1
|
0
|
32
|
33
|
31
|
4
|
0
|
3
|
2
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
1
|
0
|
2
|
3
|
3
|
3
|
1
|
1
|
1
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
12
|
16
|
19
|
11
|
1
|
0
|
0
|
|
| Total Assets |
7
N/A
|
12
+65%
|
8
-28%
|
46
+451%
|
117
+152%
|
221
+90%
|
154
-30%
|
222
+44%
|
139
-37%
|
87
-38%
|
56
-36%
|
55
-1%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
0
|
1
|
1
|
1
|
5
|
3
|
2
|
5
|
3
|
1
|
1
|
|
| Accrued Liabilities |
1
|
3
|
2
|
4
|
7
|
12
|
22
|
21
|
22
|
9
|
6
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
4
|
0
|
2
|
1
|
7
|
0
|
0
|
0
|
0
|
5
|
0
|
10
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
9
|
1
|
1
|
|
| Total Current Liabilities |
6
|
3
|
6
|
6
|
15
|
17
|
25
|
22
|
37
|
26
|
8
|
17
|
|
| Long-Term Debt |
1
|
5
|
8
|
9
|
12
|
70
|
71
|
72
|
79
|
38
|
34
|
20
|
|
| Other Liabilities |
1
|
1
|
1
|
1
|
0
|
29
|
29
|
27
|
6
|
4
|
6
|
6
|
|
| Total Liabilities |
7
N/A
|
9
+23%
|
14
+67%
|
16
+11%
|
27
+71%
|
116
+331%
|
125
+7%
|
122
-2%
|
123
+1%
|
68
-45%
|
48
-29%
|
43
-11%
|
|
| Equity | |||||||||||||
| Common Stock |
22
|
44
|
51
|
118
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
23
|
42
|
59
|
92
|
134
|
201
|
296
|
400
|
542
|
587
|
629
|
668
|
|
| Additional Paid In Capital |
1
|
2
|
2
|
4
|
224
|
306
|
325
|
500
|
559
|
606
|
637
|
680
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
3
+1 550%
|
6
N/A
|
31
N/A
|
90
+193%
|
105
+17%
|
30
-72%
|
100
+237%
|
17
-83%
|
19
+13%
|
8
-61%
|
12
+64%
|
|
| Total Liabilities & Equity |
7
N/A
|
12
+65%
|
8
-28%
|
46
+451%
|
117
+152%
|
221
+90%
|
154
-30%
|
222
+44%
|
139
-37%
|
87
-38%
|
56
-36%
|
55
-1%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
3
|
6
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
